Overview
Kaleido develops a wearable insulin pump designed for people who need insulin therapy. The pump holds 200 units of rapid-acting insulin, runs on a three-day battery life, and is water-resistant for up to one hour. It works by delivering insulin continuously through easy-to-apply infusion sets, using micro pulse technology to maintain consistent dosing. Revenue comes from selling the pumps to patients prescribed by healthcare professionals. The device aims to provide a smaller, simpler, and more flexible alternative to traditional insulin pumps, improving convenience and daily living for people with diabetes. Its goal is to make insulin therapy easier to manage and more comfortable so users can live with fewer constraints from their treatment.
Work here?Claim your company
Simplify's take
What believers are saying
- ViCentra raised a $98 million Series D, plus a $13 million extension in January 2026.
- By October 2026, 3,918 users generated strong real-world outcomes and low hypoglycemia.
- Commercial shipments expanded in Germany, the Netherlands, and France during 2026, widening installed base.
What critics are saying
- ViCentra still serves only adults; pediatric approval remains a roadmap item after 2026.
- The U.S. market remains future work, so Tandem, Insulet, and Medtronic stay unchallenged.
- Any DBLG2, Dexcom G7, or pump reliability failure would cripple trust and delay expansion.
What makes ViCentra unique
- Kaleido pairs patch-pump hardware with Diabeloop DBLG2 and Dexcom G7, launched May 2026.
- Its twin-rechargeable-pump design and colorful handset make therapy less clinical than rivals.
- Phillips Medisize manufacturing began May 28, 2026, scaling consumables for over 17,000 users.
Help us improve and share your feedback! Did you find this helpful?